Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable?

Abstract

Background:

Vigabatrin (VGB) is currently the most widely prescribed first-line medication for individuals with infantile spasms (IS) and especially for those with tuberous sclerosis complex (TSC), with demonstrated efficacy. Meanwhile, its adverse events, such as vigabatrin-associated brain abnormalities on magnetic resonance imaging (MRI; VABAM), have also been widely reported.

Objectives:

The objectives of this study were to observe the occurrences of VABAM in patients with IS caused by TSC (IST) and further explore the associated risk factors.

Methods:

Children with IS receiving VGB were recruited from our institution; clinical, imaging, and medication data were collected. Cerebral MRI was reviewed to determine the occurrence of VABAM. Group comparisons (IS caused by TSC and other etiologies) were performed; subgroup analyses on IST were also performed. Next, a retrospective cohort study of children taking VGB was conducted to explore risk/protective factors associated with VABAM.

Results:

The study enrolled 172 children with IS who received VGB. VABAM was observed in 38 patients (22.1%) with a peak dosage of 103.5 ± 26.7 mg/kg/day. Subsequent analysis found the incidence of VABAM was significantly lower in the 80 patients with IST than in the 92 patients with IS caused by other etiologies (10% versus 32.6%, p-value < 0.001). In subgroup analyses within the IST cohort, VABAM was significantly lower in children who received concomitant rapamycin therapy. Univariate and multivariate logistic regression analysis of the 172 IS children showed that treatment with rapamycin was the independent factor associated with a lower risk of VABAM; similar results were observed in the survival analysis.

Conclusion:

The incidence of VABAM was significantly lower in IST patients. Further research is needed to examine the mechanisms that underlie this phenomenon and to determine if treatment with rapamycin may reduce the risk of VABAM.

Keywords

incidence infantile spasms rapamycin tuberous sclerosis complex VABAM

Highlights

Rapamycin is potentially a protective factor associated with VABAM.

The incidence of VABAM in patients with infantile spasms caused by tuberous sclerosis complex was lower than in other etiologies.

The risk factors associated with VABAM were unclear, but VABAM may occur even at the conventional dosage of VGB (i.e. ≤150/kg/day).

Introduction

Infantile spasms (IS), also identified as Infantile epileptic spasms syndrome by the International League Against Epilepsy, is characterized by the onset of epileptic spasms between 1 and 24 (peak 3 and 12) months of age and caused by more than 200 etiologies, and can be divided into two major categories based on etiology: known (symptomatic) and unknown (cryptogenic).^1–4 Among the known etiologies, tuberous sclerosis complex (TSC) is among the leading causes of IS.^2,4 Standard first-line systemic therapy for IS includes hormonal therapy (e.g. adrenocorticotropic hormone and prednisolone) and vigabatrin (VGB).^4,5 VGB has shown clinical effectiveness in children with IS, especially when caused by TSC.^6–8

With general use, however, adverse events associated with VGB were reported, the most common being sedation, somnolence, irritability, insomnia, sleep disorder, constipation, lethargy, decreased appetite, and hypotonia.⁹ VGB-specific side effects also include peripheral visual field defects and recently reported vigabatrin-associated brain abnormalities in magnetic resonance imaging (MRI; VABAM).¹⁰ Typical VABAM manifest as reversible high T2-weighted imaging (T2WI) signal and diffusion restriction of the thalamus, basal ganglia, brainstem, and cerebellar dentate nucleus.^11–14 Although some studies have shown that VABAM is not accompanied by clinical symptoms, other studies on VABAM cases provide evidence that VABAM is associated with movement disorders, encephalopathy, dysautonomia, or death.^13,15 Currently, there are no effective therapeutic drugs available to prevent or treat VABAM, and clinicians wait for the spontaneous regression of VABAM by discontinuation of VGB.¹³

The incidence of VABAM in infants can be as high as 21–32.5%.^13,16–19 Given the clinical efficacy of VGB in seizure control of IS, especially in IS caused by TSC (IST),^4,6,7,20 discontinuation caused by VABAM may result in the exacerbation or relapse of seizures. Therefore, it is essential to further explore VABAM in IST. Regrettably, only scattered cases are reported^{11,12,14,21,22} and no study has focused on this aspect. In our previous study, we discovered that the peak dosage of VGB is the risk factor for VABAM, and the incidence was 32.5%.¹⁹ However, patients with IST were not incorporated into the study. When VABAM was observed in a larger patient cohort in our medical center, we found that the incidence in IST was much lower than in patients with IS caused by the other etiologies (ISO). Our medical center registered and carried out the first clinical study using rapamycin (Reference No. ChiCTR-IPR-15007241), an mTOR inhibitor, to treat patients with TSC in China. As a result, most of the IST patients above had received the combination treatment with rapamycin.

To better understand VABAM, we conducted this study in a larger cohort by incorporating IST patients into the previous study cohort. A retrospective cohort and case–control study were designed and conducted to identify risk factors for the occurrence of VABAM.

Methods

Study subjects

All children with IS who visited our hospital (including patients who received an initial dose of VGB and those with a VGB exposure history referred by the other institution) were included in this study. Criteria for inclusion or exclusion of subjects were synthesized based on our previous study.¹⁹ Inclusion criteria were: (1) clear diagnosis of IS based on the clinical symptoms and electroencephalogram results (as Infantile epileptic spasms syndrome defined by International League Against Epilepsy in 2022),³ (2) exposure more than 30 days and still taking VGB at the time of this study, and (3) at least one cerebral MRI examination completed before or during VGB exposure. The exclusion criteria were: (1) time of first cerebral MRI review after VGB exposure is more than 1 year, (2) time of first cerebral MRI review after VGB exposure has not reached 30 days, (3) children with IS caused by congenital metabolic diseases, and (4) children with VGB exposure history referred by another institution that did not perform cerebral MRI before an initial dose of rapamycin therapy in our hospital.

Observation indicators, diagnosis of TSC, and identification of VABAM

Clinical data were recorded, including IS etiology; age at first VGB exposure; duration, cumulative, and peak dosage of VGB exposure; other anti-seizure medications (ASMs); hormonal therapy when taking VGB; and concomitant rapamycin therapy of all children.

The diagnosis of TSC was established in a proband with one of the following diagnostic criteria: (1) presence of any two of the major clinical features listed by the International Tuberous Sclerosis Complex Consensus Group,²³ (2) one major clinical feature and two or more minor clinical features,²³ or (3) identification of a heterozygous pathogenic variant in TSC1 or TSC2 by molecular genetic testing.²³

VABAM was identified when a comparison of cerebral MRI before and after VGB exposure showed new onset bilateral symmetrical thalamus, basal ganglia, brainstem, or cerebellar dentate nucleus T2WI, or diffusion-weighted imaging (DWI) high signal in these areas.²⁴ The imaging data of subjects were reviewed independently by two highly experienced senior pediatric neurologists (Drs. Xiu-Yu Shi and Guang Yang, with more than 20 years of clinical experience). When results differed between the two raters, the final identification of VABAM was confirmed by the chief pediatric neurologist (Dr. Li-Ping Zou, with more than 40 years of clinical experience). In addition to knowing that all patients had VGB exposure, all the other treatment protocols were blinded to the above three assessors.

When VABAM was identified on review of MRI, progress notes in the medical record were serially reviewed in the search for new-onset symptoms consistent with VABAM (i.e. movement disorders, lethargic, unresponsive, and respiratory distress or arrest). If the patient had the above symptoms, he (or she) would be considered symptomatic VABAM, otherwise would be considered asymptomatic VABAM.

Statistical analysis

SPSS 26.0 statistical software and the R programming language (version 4.1.2) were used for analysis, and the data description was expressed in the form of means (standard deviations) for normally distributed variables or medians (interquartile ranges) for non-normally distributed variables. The independent two-sample t-test, chi-square test, or Wilcoxon rank-sum test was conducted to analyze the above observation indicators. Univariate logistic regression analysis was conducted to assess for collinearity and filter variants; multivariate logistic regression analysis was performed to clarify the risk factors of VABAM. Variable selection was conducted by least absolute selection and shrinkage operator (LASSO) in multivariate logistic regression. Kaplan–Meier (KM) curves and log-rank tests were used for the survival analysis of VABAM. A p-value of less than 0.05 indicated statistical significance.

Results

A total of 533 children with IS who had VGB exposure were screened. Of these, 390 underwent cerebral MRI before VGB exposure and during follow-up. Among these 390 children, 18 with VGB exposure for less than 30 days, 193 with VGB exposure for more than 1 year during cerebral MRI review, and 7 without MRI review before the initiation of rapamycin were excluded. All patients who needed to withdraw VGB for suspected symptomatic VABAM had performed MRI reexamined and were enrolled in the study. Ultimately, 172 children were included in this study (Figure 1), and 38 (22.1%) developed VABAM (The two senior investigators agreed on the evaluation results of VABAM in 170 children, the other 2 children were identified as non-VABAM by the chief investigators). VGB peak dosage was 103.5 (mean) ± 26.7 (standard deviation) mg/kg/day (37 with the peak dosage ⩽ 150 mg/kg/day), and the duration of VGB exposure was 170 ± 12 days. Of the 172 children, IS in 80 was caused by TSC (IST), and IS in 92 was caused by other etiologies (ISO). In agreement with our previously reported data, treatment of IS commonly exhibits a particular preference for concomitant ASM therapies; Valproate (VPA, n = 88, 51.2%) and topiramate (TPM, n = 103, 59.9%) were used more frequently than other ASMs (less than 20%).

Figure 1.

Flow chart of screening of the patients with infantile spasms.

In the IST group (56 males and 24 females), 8 children (10%) developed VABAM. Age at first VGB exposure was a median of 10 months (interquartile range or IQR: 6–17.75 months); 51 cases (63.8%) started taking VGB for the first time in infancy (⩽ 12 months). VPA and TPM were used concomitantly with VGB in 32 (40%), and 30 (37.5%) patients, the dosage of VPA and TPM was 35.72 ± 3.65 and 6.26 ± 0.70 mg/kg/day, respectively. The peak dosage of VGB was 99.1 ± 30.1 mg/kg/day, the duration of exposure before MRI review was 261 ± 102 days, and the corresponding cumulative dosage was a median of 256 g (IQR: 130 g, 365 g). Thirteen cases (16.3%) received hormonal therapy when taking VGB. Concomitant rapamycin therapy was observed in 60 patients.

In the ISO group (53 males and 39 females), wherein 41 cases (44.6%) had known etiologies and 51 (55.4%) had unknown etiology, 30 cases (32.6%) developed VABAM. The age at first VGB exposure was 9 months (6.1, 14.875 months); 62 (67.4%) patients started taking VGB for the first time in infancy (⩽ 12 months). VPA and TPM were used when taking VGB in 56 (60.9%) and 73 (79.3%) patients, and the dosage of VPA and TPM was 35.55 ± 2.83 and 6.37 ± 0.32 mg/kg/day, respectively. The peak dosage of VGB was 96.7 ± 36.7 mg/kg/day, the duration of exposure before MRI review was 134 ± 92 days, and the corresponding cumulative dosage was 97.6 g (46.1 g, 200.5 g). A total of 37 cases (40.2%) received hormonal therapy when taking VGB. There were no children in the ISO group who received concomitant rapamycin therapy.

The incidence of VABAM was much lower in the IST group than in the ISO group (p < 0.001, Table 1). Significant differences emerged for the medication strategy between the IST and ISO groups; the use of VPA, TPM, and hormonal therapy were significantly less frequent in the IST group, but the IST group had more concomitant rapamycin therapy than the ISO group (p = 0.006, < 0.001, < 0.001, and < 0.001, Table 1). The dosage of VPA and TPM were not significantly different between IST and ISO groups (both p > 0.05, Table 1). The duration of VGB exposure and the cumulative dosage was significantly increased in the IST group (p < 0.001, both, Table 1), but the age at first exposure and peak dosage were not significantly different between IST and ISO groups (both p > 0.05, Table 1).

Table 1.

Comparison of clinical characteristics between the IST and ISO groups.

	IST group (n = 80)	ISO group(n = 92)	Test statistics	p-value
Gender (male/female)	56/24	53/39	2.831	0.092^a
Etiology (known/unknown)	80/0	41/51	< 0.001	< 0.001^b
Age at first VGB exposure (months) (month)	10 (6,17.75)	9 (6.1,14.875)	–0.642	0.242^c
≤ 12 months	51	62	0.252	0.616^a
> 12 months	29	30
VPA exposure when taking VGB	32	56	7.459	0.006 ^a
Dosage of VPA exposure (mg/kg/day)	35.72 ± 3.65 (n = 32)	35.55 ± 2.83 (n = 56)	0.273	0.813^d
TPM exposure when taking VGB	30	73	31.194	< 0.001^a
Dosage of TPM exposure (mg/kg/day)	6.26 ± 0.70 (n = 30)	6.37 ± 0.32 (n = 73)	–0.772	0.444^d
Peak dosage (mg/kg/day)	99.1 ± 30.1	96.7 ± 36.7	0.477	0.634^d
Days of VGB exposure	261 ± 102	134 ± 92	8.517	< 0.001^d
Cumulative dosage of VGB (g)	256 (130, 365)	97.6 (46.1, 200.5)	–5.602	< 0.001^c
Hormonal therapy when taking VGB	13	37	11.921	< 0.001^a
Concomitant rapamycin therapy	60	0	105.964	< 0.001^a
VABAM	8	30	12.71	< 0.001^a

Bold p value denotes statistically significant; data are expressed as count number, mean ± standard deviation, or median (IQR).

IQR, interquartile range; ISO, infantile spasms caused by the other etiologies; IST, infantile spasms caused by tuberous sclerosis complex; TPM, topiramate; TSC, tuberous sclerosis complex; VABAM, vigabatrin-associated brain abnormalities on magnetic resonance imaging; VGB, vigabatrin; VPA, valproate.

Chi-square test.

Fisher’s exact test.

Wilcoxon rank-sum test.

Independent two-sample t-test.

Sub-group analysis of the IST group showed that 3 in 60 cases with concomitant rapamycin therapy (5%) developed VABAM, compared with 5 in 20 patients without rapamycin therapy (25%; p = 0.021, Table 2). Children who received concomitant rapamycin therapy appear to have the lowest incidence of VABAM compared with other groups (Figure 2). Aside from having a longer duration of VGB exposure in those children with concomitant rapamycin therapy (p = 0.004, Table 2), no other significant differences were found between the two groups (p > 0.05, Table 2).

Table 2.

Comparison of clinical characteristics between the patients with and without rapamycin therapy.

	Group with concomitant rapamycin therapy (n = 60)	Group without rapamycin therapy (n = 20)	Test statistics	p-value
Gender (male/female)	41/19	15/5	0.317	0.573^a
Age at first VGB exposure (months)	10.5 (6, 19.5)	10 (4.5, 14)	0.775	0.586^c
≤⩽ 12 months	37	14	0.451	0.502^a
> 12 months	23	6
VPA exposure when taking VGB	24	8	< 0.001	1^a
Dosage of VPA exposure (mg/kg/day)	35.22 ± 3.63 (n = 24)	37.23 ± 3.49 (n = 8)	–1.369	0.181^d
TPM exposure when taking VGB	21	9	0.640	0.424^a
Dosage of TPM exposure (mg/kg/day)	6.24 ± 0.81 (n = 21)	6.31 ± 0.38 (n = 9)	–0.266	0.792^d
Peak dosage (mg/kg/day)	97.3 ± 32.1	104.8 ± 22.8	–0.965	0.338^d
Days of VGB exposure	279 ± 95	205 ± 104	2.979	0.004 ^d
Cumulative dosage of VGB (g)	269.9 ± 134.7	229.3 ± 181.6	1.065	0.290^c
Hormonal therapy when taking VGB	9	4	0.276	0.600^a
VABAM	3	5	0.021	0.021 ^b

Bold p-value denotes statistically significant; data are expressed as count number, mean ± standard deviation, or median (IQR).

IQR, interquartile range; TPM, topiramate; TSC, tuberous sclerosis complex; VABAM, vigabatrin-associated brain abnormalities on magnetic resonance imaging; VGB, vigabatrin; VPA, valproate.

Chi-square test.

Fisher’s exact test.

Wilcoxon rank-sum test.

Independent two-sample t-test.

Figure 2.

Incidence rates of VABAM in various groups.

Considering VABAM as an outcome event, the univariate logistic regression analysis showed that TPM or hormonal therapy when taking VGB were risk factors associated with VABAM (p = 0.003 and 0.002, respectively; Table 3); concomitant rapamycin therapy and IST case were protective factors (both p < 0.001, Table 3). After LASSO regression analysis, the indicators of IST, TPM exposure when taking VGB, hormonal therapy when taking VGB, age at first VGB exposure, VGB exposure at infancy, cumulative dosage of VGB, peak dosage of VGB, and concomitant rapamycin therapy were entered in the final multivariate logistic regression analysis. This analysis showed that concomitant rapamycin therapy was the independent protective factor associated with VABAM (p = 0.019, odds ratio = 0.152, 95% confidence interval: [0.028, 0.715], Table 3).

Table 3.

Logistic regression analysis of VABAM risk factors in children with infantile spasms taking vigabatrin.

	Odds ratio	95% confidence interval for odds ratio		p-value
		Lower	Upper	p-value
Univariate logistic regression analysis
Gender	0.856	0.411	1.821	0.680
Etiology	0.563	0.266	1.213	0.136
TSC	0.23	0.092	0.516	< 0.001
Age at first VGB exposure	0.998	0.994	1.001	0.163
VGB exposure at infant period	1.614	0.742	3.75	0.243
VPA exposure when taking VGB	1.417	0.688	2.971	0.348
Dosage of TPM exposure (mg/kg/day, n = 88)	0.363	0.375	1.433	0.733
TPM exposure when taking VGB	3.813	1.645	9.973	0.003
Dosage of VPA exposure (mg/kg/day, n = 103)	0.864	0.845	1.152	0.987
Peak dosage of VGB	1.006	0.996	1.017	0.243
Days of VGB exposure	0.998	0.995	1.001	0.198
Cumulative dosage of VGB	0.998	0.996	1.001	0.217
Hormonal therapy when taking VGB	3.322	1.567	7.102	0.002
Concomitant rapamycin therapy	0.116	0.027	0.342	< 0.001
Multivariate logistic regression analysis (with LASSO variable selection)
TSC	0.788	0.214	2.557	0.702
TPM exposure when taking VGB	2.078	0.755	6.293	0.171
Hormonal therapy when taking VGB	2.132	0.913	5.024	0.080
Age at first VGB exposure	0.746	0.265	2.096	0.574
VGB exposure at infant period	1.234	0.313	4.928	0.764
Cumulative dosage of VGB	1.529	0.93	2.58	0.101
Peak dosage of VGB	1.004	0.99	1.017	0.588
Concomitant rapamycin therapy	0.152	0.028	0.715	0.019

Bold p-value denotes statistically significant.

LASSO, least absolute selection and shrinkage operator; TPM, topiramate; TSC, tuberous sclerosis complex; VABAM, vigabatrin-associated brain abnormalities on magnetic resonance imaging; VGB, vigabatrin; VPA, valproate.

KM curves showed that cases who received concomitant rapamycin therapy had a higher percentage of freedom from developing VABAM than those cases without (95% versus 68.8%, p < 0.001, Figure 3).

Figure 3.

Kaplan–Meier survival curves for VABAM in patients with vigabatrin treatment. (a) With or without concomitant rapamycin therapy and VABAM-free survival in patients with vigabatrin treatment. (b) Number of patients with or without concomitant rapamycin therapy at VABAM risk during VGB exposure.

There were 13 (34.2%) patients with symptomatic VABAM; the other 25 (65.8%) were asymptomatic. Among the symptomatic VABAM patients, seven had only movement disorder, three with motor and non-motor symptoms (lethargic and unresponsive), and three with non-motor symptoms (two lethargic and unresponsive and one respiratory distress/arrest). No group differences in the above-observed measures, which were used between IST and ISO groups, emerged between symptomatic and asymptomatic VABAM groups (Table S1). Logistic regression analysis showed no risk/protective factor associated with symptomatic VABAM in the patients with VABAM (n = 38, Table S2). In the whole VGB exposure cohort (n = 172), it showed that concomitant hormonal therapy (p = 0.012, odds ratio = 4.457, 95% confidence interval: [1.381, 14.385]) and TPM exposure (p = 0.037, odds ratio = 8.967, 95% confidence interval: [1.138, 70.64], Table S3) were the risk factors with symptomatic VABAM, but not confirmed by further final multivariate logistic regression analysis (Table S3).

Discussion

Previous studies have shown that the incidence of VABAM was between 22% and 32%,^17,25 and a recent meta-analysis found a pooled rate of 21% in seven studies.¹⁴ In our cohort of 172 cases in this study, 38 developed VABAM, and the incidence of 22.1% was generally consistent with previous studies.^14,17,25 When all subjects were classified into two groups (IST and ISO), significant differences emerged in the distribution of children with VABAM. The incidence of VABAM in the ISO group (32.6%) is slightly higher than in previous reports but much lower than in the IST group (10%). Furthermore, subgroup analyses showed that concomitant rapamycin therapy seems likely to cause this discrepancy.

Previous studies reached inconsistent conclusions regarding risk factors associated with VABAM. Pearl et al.¹⁷ concluded that young age and relatively high doses appear to be risk factors. Hussain et al.¹³ pointed out that the occurrence of VABAM is related to the peak dosage of VGB, notably higher than 175 mg/kg/day. The meta-review performed by Biswas et al.¹⁴ concluded that risk factors for VABAM were less than 12 months of age, unknown etiology of IS, and higher peak dosage of VGB (> 170 mg/kg/day). However, our previous study showed only peak dosage of VGB as an independent risk factor of VABAM, even using the conventional dosage of VGB (i.e. 50–150 mg/kg/day).¹⁹ Although that study found a significant difference in the incidence of VABAM between the IST and ISO groups, no significant differences in the indicators mentioned above were observed. In addition, despite the ISO group having a shorter duration and cumulative dosage of VGB exposure, we had previously demonstrated that these indicators were not significantly associated with the occurrence of VABAM.^13,19 The major therapeutic strategies for VABAM were VGB discontinuation; a higher rate of VABAM in the ISO group could lead to more discontinuation of VGB, which in turn would lead to decreased duration and cumulative dosage of VGB exposure in the ISO group.

In this study, treatment regimens differed in both groups, and increased usage of TPM, VPA, and hormonal therapy was observed in the ISO group. Current guidelines recommend VGB as the preferred first-choice medication for IST.^4,6,7 According to antiepileptic-to-treat principles, ASM treatment must be initiated as monotherapy; then, combination therapy can be initiated when monotherapy fails.^26,27 Furthermore, hormonal therapy, but not VGB, was the first treatment of choice for ISO, especially in the unknown etiologies.^4,28–31 These reasons caused the disparities in pharmaceutical therapy between groups in this study.

In the final regression analysis, we found no risk factors associated with VABAM, but it is noted that 37 of 38 children with VABAM had the conventional dosage of VGB (i.e. ⩽ 150 mg/kg/day). We observed group differences in the concomitant rapamycin therapy between the two groups (ISO and IST). The final regression analysis also showed that concomitant rapamycin therapy could be the protective factor associated with VABAM. KM survival analysis indicated significantly different survival between children with or without concomitant rapamycin therapy. To our knowledge, this is the first study to report this phenomenon.

As we mentioned above, all the children with concomitant rapamycin therapy were IST. Hence, we attempted to understand the incidence of VABAM in children with TSC by reviewing the previous literature. Regrettably, only two case reports^12,21 and three studies were found.^11,13,17 Pearl et al.¹⁷ reported that none of the seven TSC children developed VABAM; the count is 1 of 12 in the report by Hussain et al.¹³ and 2 of 24 in that by Dracopoulos et al.¹¹ Although the incidence of VABAM in the IST group seemed consistent with the previous study, after sub-group analysis, 5 in those 20 without concomitant rapamycin therapy (25%) developed VABAM and 3 in those 60 with it (5%). The results of our study may have a weaker tendency for concomitant rapamycin therapy caused by the lower incidence of VABAM in the IST group, but it needs further verification in more cases. Fortunately, we note that there was a study of VGB use to prevent epilepsy in infants with TSC,³² and we very much look forward to their follow-up work on VABAM.

Although the previous study demonstrated that VABAM is often reversible and mainly asymptomatic,^6,11,13,14 a recent study showed there were 19 (43.2%) patients who had obvious symptoms in 44 VABAM patients,³³ which was also observed in our study (34.2%). For symptomatic VABAM, Hussain et al.¹³ considered it might be associated with concomitant hormonal therapy. In our study, we did not observe any association between any factors and symptomatic VABAM; it could be possible interference by other treatment protocols (i.e. concomitant rapamycin therapy). Thus, conclusions from this subset should be taken with caution.

Rapamycin-based (an mTOR inhibitor) therapy has shown benefits for patients with TSC, especially those with renal cancer carcinoma, TSC, and lymphangioleiomyomatosis-related tumors.^26,34–36 Beyond that, rapamycin could be useful for seizure control in TSC in both animal and human studies.^37–40 Several ASMs are the substrate and inducer of CYP3A4 and phosphoglycolate phosphatase, which may influence the metabolism of mTOR inhibitor,^41,42 but this effect was not observed with VGB.⁴³ Vogel et al.⁴⁴ showed that increased expression of transcripts in the mTOR pathway and autophagy was suppressed in the human retinal pigment epithelial cells ARPE19 cultured in VGB, and this effect could be attenuated by the mTOR inhibitor (Torin 2). Both animal and human studies have shown that VGB could induce intramyelinic edema,^15,45–48 and studies showed the injury of myelin was associated with autophagy.^49,50 Thus, we presume rapamycin could induce autophagy via partial mTOR inhibition to prevent the occurrence of VABAM. Paradoxically, the TSC patients with mTOR hyperactivation should have a higher incidence of VABAM based on that assumption, but this is not the case. We speculated that these seemingly conflictive results might be because TSC patients inherently have brain abnormalities on MRI, and therefore VABAM could be overlooked.

Disruption in the mTOR pathway is believed to enhance neuronal excitability and promote epileptogenesis in TSC patients due to an imbalance of GABAergic inhibition and glutamatergic excitation.⁵¹ For this reason, mTOR inhibitors were introduced to treat various manifestations of TSC especially, epilepsy.^37,52–55 Our early study had demonstrated that sirolimus treatment for TSC effectively modified the disease by preventing IS, delaying seizure onset, and relieving its severity.⁵⁶ Based on the above research results, rapamycin might be a beneficial therapeutic option in treating IST patients, especially in combination with vigabatrin, for its potential role in the prevention of VABAM.

This study has several limitations. First, this is a relatively small, single-center study; the strength of the conclusions is thus limited, and the results require confirmation by further investigations. Second, this was a retrospective study based on an observed clinical phenomenon, so some children with VGB exposure history but without cerebral MRI examination before an initial dose of rapamycin therapy were excluded; the sample number was small, and the bias should be small, but it should not be dismissed. Third, 143 patients with VGB but without cerebral MRI before VGB exposure or during follow-up were excluded from this study. Because of the study’s retrospective nature, this may be unavoidable and may bias the results; thus, the results need to be interpreted with caution. Fourth, symptomatic VABAM should be further carefully investigated, such as more detail of clinical symptoms and the association with the location of MRI abnormalities or treatment protocols. Finally, although interesting phenomena have been observed, we have encountered difficulties in elucidating specific mechanisms, and additional study is needed to verify our hypothesis. Detailed follow-up work along this line is underway in our team.

Conclusion

In conclusion, in this study with a larger patient cohort, no risk factor associated with VABAM was observed; consistent with our previous study, VABAM may occur even at the conventional dosage of VGB (i.e. ⩽ 150 mg/kg/day). The incidence of VABAM was much lower in IST patients. This finding may be related to treatment with rapamycin, which could reduce the risk of VABAM. We anticipate that our investigation will motivate future studies on the determinants identified in our research and that these studies can explore the mechanisms behind the protective effect.

Supplemental Material

sj-docx-1-tan-10.1177_17562864221138148 – Supplemental material for Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable?

Supplemental material, sj-docx-1-tan-10.1177_17562864221138148 for Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable? by Lin Wan, Wen He, Yang-Yang Wang, Yong Xu, Qian Lu, Meng-Na Zhang, Qiu-Hong Wang, Shuo Dun, Li-Ying Liu, Xiu-Yu Shi, Jing Wang, Lin-Yan Hu, Bo Zhang, Guang Yang and Li-Ping Zou in Therapeutic Advances in Neurological Disorders

Footnotes

Acknowledgements

None.

Declarations

ORCID iD

Lin Wan

Supplemental material

Supplemental material for this article is available online.

References

Berg

Berkovic

Brodie

, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676–685.

Scheffer

Berkovic

Capovilla

, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512–521.

Zuberi

Wirrell

Yozawitz

, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63: 1349–1397.

Hussain

SA.

Treatment of infantile spasms. Epilepsia Open 2018; 3: 143–154.

Riikonen

Infantile spasms: outcome in clinical studies. Pediatr Neurol 2020; 108: 54–64.

Pesaturo

Spooner

Belliveau

Vigabatrin for infantile spasms. Pharmacotherapy 2011; 31: 298–311.

Gaily

Vigabatrin monotherapy for infantile spasms. Expert Rev Neurother 2012; 12: 275–286.

Ohtsuka

Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: primary short-term study and extension study. Epilepsy Behav 2018; 78: 134–141.

Elterman

Shields

Bittman

, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010; 25: 1340–1347.

10.

Riikonen

Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs 2014; 28: 279–290.

11.

Dracopoulos

Widjaja

Raybaud

, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 2010; 51: 1297–1304.

12.

Thapa

Khanna

PC.

Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis. Pediatr Radiol 2010; 40(Suppl. 1): S153.

13.

Hussain

Tsao

, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia 2017; 58: 674–682.

14.

Biswas

Yossofzai

Vincent

, et al. Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis. Expert Rev Neurother 2020; 20: 1315–1324.

15.

Bhalla

Skjei

Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: three cases and review of the literature. Epilepsia 2020; 61: e159–e164.

16.

Desguerre

Marti

Valayannopoulos

, et al. Transient magnetic resonance diffusion abnormalities in West syndrome: the radiological expression of non-convulsive status epilepticus. Dev Med Child Neurol 2008; 50: 112–116.

17.

Pearl

Vezina

Saneto

, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50: 184–194.

18.

Dill

Datta

Weber

, et al. Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms. Eur J Paediatr Neurol 2013; 17: 311–315.

19.

Wan

, et al. Risk of vigabatrin-associated brain abnormalities on MRI: a retrospective and controlled study. Epilepsia 2022; 63: 120–129.

20.

Northrup

Koenig

Pearson

, et al. Tuberous sclerosis complex. Seattle, WA: University of Washington, 1993.

21.

Simao

Zarei Mahmoodabadi

Snead

, et al. Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin. AJNR Am J Neuroradiol 2011; 32: 199–203.

22.

Craft

Cardenas

AM.

Vigabatrin-associated reversible MRI abnormalities in an infant with tuberous sclerosis. J Radiol Case Rep 2021; 15: 1–6.

23.

Northrup

Krueger

and International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 243–254.

24.

Liu

Zhang

, et al. Reversible abnormalities in brain magnetic resonance imaging of children with infantile spasms during treatments with Vigabatrin. Chin J Appl Clin Pediatr 2020; 35: 894–898.

25.

Wheless

Carmant

Bebin

, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50: 195–205.

26.

Glauser

Ben-Menachem

Bourgeois

, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551–563.

27.

Moavero

Pisani

, et al. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 2018; 17: 1015–1028.

28.

Mackay

Weiss

, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78: 1974–1980.

29.

Knupp

Coryell

Nickels

, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol 2016; 79: 475–484.

30.

Hancock

Osborne

Edwards

SW.

Treatment of infantile spasms. Cochrane Database Syst Rev 2013; 6: CD001770.

31.

Lux

Edwards

Hancock

, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364: 1773–1778.

32.

Kotulska

Kwiatkowski

Curatolo

, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021; 89: 304–314.

33.

Reyes Valenzuela

Crespo

Princich

, et al. Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome. Epilepsy Behav 2022; 129: 108606.

34.

McCormack

Inoue

Moss

, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595–1606.

35.

Wang

Chen

, et al. Initial dosage recommendation for sirolimus in children with tuberous sclerosis complex. Front Pharmacol 2020; 11: 890.

36.

Sugalska

Tomik

Jóźwiak

, et al. Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex – a systematic review. Int J Environ Res Public Health 2021; 18: 4907.

37.

Chen

Wang

, et al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure 2020; 79: 20–26.

38.

Akman

Briggs

Mowrey

, et al. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia 2021; 62: 1985–1999.

39.

Chen

Wang

Zhu

, et al. Population pharmacokinetics and initial dose optimization of sirolimus improving drug blood level for seizure control in pediatric patients with tuberous sclerosis complex. Front Pharmacol 2021; 12: 647232.

40.

Koene

Niggl

Wallaard

, et al. Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis. JCI Insight 2021; 6: e150120.

41.

Lechuga

Franz

DN.

Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. Expert Rev Neurother 2019; 19: 913–925.

42.

Franz

Lawson

Yapici

, et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia 2018; 59: 1188–1197.

43.

Bartoli

Gatti

Cipolla

, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997; 38: 702–707.

44.

Vogel

Ainslie

Schmidt

, et al. mTOR inhibition mitigates molecular and biochemical alterations of vigabatrin-induced visual field toxicity in mice. Pediatr Neurol 2017; 66: 44–52.

45.

Pearl

Poduri

Prabhu

, et al. White matter spongiosis with vigabatrin therapy for infantile spasms. Epilepsia 2018; 59: e40–e44.

46.

Preece

Houseman

King

, et al. Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse 2004; 53: 36–43.

47.

Walker

Kälviäinen

Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand Suppl 2011; 192: 72–82.

48.

Horton

Rafay

Del Bigio

MR.

Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009; 24: 1543–1546.

49.

Hantke

Carty

Wagstaff

, et al. c-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy. Brain 2014; 137: 2922–2937.

50.

Ding

Huang

Xia

, et al. Transfer of α-synuclein from neurons to oligodendrocytes triggers myelin sheath destruction in methamphetamine administration mice. Toxicol Lett 2021; 352: 34–45.

51.

Curatolo

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 2015; 52: 281–289.

52.

Krueger

Wilfong

Holland-Bouley

, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74: 679–687.

53.

French

Lawson

Yapici

, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 2153–2163.

54.

Overwater

Rietman

Bindels-De Heus

, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology 2016; 87: 1011–1018.

55.

Sadowski

Sijko

Domańska-Pakieła

, et al. Antiepileptic effect and safety profile of rapamycin in pediatric patients with tuberous sclerosis complex. Front Neurol 2022; 13: 704978.

56.

Shen

Wang

Zhang

, et al. Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: evidence from a registry-based real-world study. Seizure 2022; 97: 23–31.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB